In follow-up data from the phase III ALEX study, an initial treatment Alecensa (alectinib) significantly reduced the risk of disease progression or death by 57 percent (hazard ratio= 0.43, 95 percent CI: 0.32-0.58) compared to crizotinib after two years of follow-up in people with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer, as assessed by the investigator.
As NCI employees and others at HHS were receiving notices of termination, national cancer organizations called on Congress “to restore stability to NIH.”
